STAT-Dx
Develops near-patient testing products for healthcare professionals.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
$191m Valuation: $191m 27.3x EV/Revenue -35.2x EV/EBITDA | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (3 %) | 195 % | 6890 % | (16 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (3404 %) | (12101 %) | (4158 %) | (78 %) | (65 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (3898 %) | 1563 % | (3584 %) | (156 %) | (200 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Stat-Dx, a subsidiary of QIAGEN, specializes in multiplex syndromic testing solutions that enable rapid and accurate diagnosis of respiratory and gastrointestinal infections. The company serves healthcare providers, clinical laboratories, and research institutions, operating primarily in the medical diagnostics market. Stat-Dx's flagship product, the QIAstat Dx Analyzer, uses advanced technology to simultaneously detect and differentiate multiple pathogens from a single sample, significantly reducing the time and labor involved in traditional diagnostic methods. The business model revolves around the sale of diagnostic panels and cartridges, which are used with the QIAstat Dx Analyzer. Revenue is generated through the sale of these consumables and the analyzer itself. Stat-Dx's innovative approach addresses the critical need for timely and precise diagnostic information, particularly in the context of infectious diseases like COVID-19. The company’s products are designed to meet the demands of both routine clinical diagnostics and urgent public health challenges, offering a valuable tool for clinicians and researchers alike.
Keywords: multiplex syndromic testing, QIAstat Dx Analyzer, respiratory infections, gastrointestinal infections, diagnostic panels, clinical laboratories, healthcare providers, pathogen detection, COVID-19, medical diagnostics.